BMS-986253 Plus Nivolumab/Ipilimumab Fails to Boost Responses in Advanced Melanoma After Prior Anti–PD-(L)1 Therapy
Source: OncLive, January 2025
BMS-986253 plus nivolumab/ipilimumab failed to improve responses or PFS in advanced melanoma after progression on or after a checkpoint inhibitor.
The addition of the anti–interleukin 8 (IL-8) monoclonal antibody BMS-986253 to nivolumab (Opdivo) and ipilimumab (Yervoy) did not lead to an improvement in responses or progression-free survival (PFS) compared with nivolumab plus ipilimumab alone in patients with advanced melanoma whose disease progressed on or after prior anti–PD-(L)1 therapy, according to data from the final analysis of part 2 of the phase 1/2 CA027-002 trial (NCT03400332).
Data presented at the 2024 ESMO Immuno-Oncology Congress showed that patients treated with BMS-986253 plus nivolumab and ipilimumab (n = 62) experienced an overall response rate (ORR) of 14.5% vs 11.7% for those given nivolumab plus ipilimumab alone (odds ratio, 1.3; 95% CI, 0.4-3.6; P = .6806). In the BMS-986253 arm, the complete response (CR), partial response, stable disease (SD), and progressive disease (PD) rates were 8.1%, 6.5%, 19.4%, and 50.0%, respectively. These respective rates were 1.7%, 10.0%, 31.7%, and 36.7% in the control arm.